Usefulness of galectin-3 immunohistochemistry in differential diagnosis between thyroid follicular carcinoma and follicular adenoma

Polish Journal of Pathology

Volumn 54, Issue 2, 2003, Pages 111-115

  Jakubiak Wielganowicz, Magdalena ^a   Kubiak, Robert ^b   Sygut, Jacek ^c   Pomorski, Lech ^b   Kordek, Radzisław ^b,d  

^a POLISH MOTHER S MEMORIAL HOSPITAL RESEARCH INSTITUTE   (Poland)

^b MEDICAL UNIVERSITY OF LODZ   (Poland)

^c Holycross Cancer Center   (Poland)

^d Department of Oncology ^*  (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 3;

ANAPLASTIC CARCINOMA; ARTICLE; BENIGN TUMOR; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT NEOPLASTIC DISEASE; ONCOCYTOMA; THYROID ADENOMA; THYROID FOLLICULAR CARCINOMA; THYROID PAPILLARY CARCINOMA;

ADENOCARCINOMA, FOLLICULAR; ADENOMA; DIAGNOSIS, DIFFERENTIAL; GALECTIN 3; HUMANS; IMMUNOHISTOCHEMISTRY; THYROID NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0141480039     PISSN: 12339687     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Aratake Y, Umeki K, Kiyoyama K, Hinoura Y, Sato S, Ohno A, Kuribayashi T, Hirai K, Nabeshima K, Kotani T: Diagnostic utility of galectin-3 and CD26/ DPPIV as preoperative diagnostic markers for thyroid nodules. Diagn Cytopathol 2002, 26, 366-372.
2. Baloch ZW, Abraham S, Roberts S, LiVolsi VA: Differential expression of cytokeratins in follicular variant of papillary carcinoma, an immunohistochemical study and its diagnostic utility. Hum Pathol 1999, 30, 1166-1171.
3. Beesley MF, McLaren KM: Cytokeratin and galectin-3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules. Histopathology 2002, 41, 236-243.
4. Cheung CC, Ezzat S, Freeman JL, Rosen IB, Asa SL: Immunohistochemical diagnosis of papillary thyroid carcinoma. Mod Pathol 2001, 14, 338-342.
5. Coli A, Bigotti G, Zuchetti F, Massi G: Galectin 3, a marker of well differentiated thyroid carcinoma, is expressed in thyroid nodules with cytological atypia. Histopathology 2002, 40, 80-87.
6. Cvejic D, Savin S, Golubovic S, Paunovic I, Tatic S, Havelka M: Galectin-3 and carcinoembryonic antigen expression in medullary thyroid carcinoma, possible relation to tumor progression. Histopathology 2000, 37, 530-535.
7. Fernandez PL, Merino MJ, Gomez M, Campo E, Medina T, Castronovo V, Sanjuan X, Cardesa A, Liu F-T, Sobel ME: Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol 1997, 181, 80-86.
8. Gasbarri A, Martegani MP, Prete F, Lucante T, Natalii PG, Bartolazzi A: Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. J Clin Oncol 1999, 17, 3494-3502.
9. Idikio H: Galectin-3 expression in human breast carcinoma, correlation with cancer histologic grade. Int J Oncol 1998, 12, 1287-1290.
10. Inohara H, Honjo Y, Yoshii T, Akahani S, Yoshida J, Hattori K, Okamoto S, Sawada T, Raz A, Kubo T: Expression of galectin-3 in fine-needle aspirates as a diagnostic marker differentiating benign from malignant thyroid neoplasms. Cancer 1999, 85, 2475-2484.
11. Irimura T, Matsushita Y, Sutton R: Increased content of an endogenous lactose-binding lectin in human colorectal carcinoma progressed to metastatic stages. Cancer Res 1991, 51, 387-393.
12. Kawachi K, Matsushita Y, Yonezawa S, Nakano S, Shirao K, Natsugoe S, Sueyoshi K, Aikou T, Sato E: Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. Hum Pathol 2000, 31, 428-433.
13. Liu F, Patterson R, Wang J: Intracellular functions of galectins. Biochim Biophys Acta 2002, 1572, 263-273.
14. Nascimento MC, Bisi H, Alves VA, Longatto-Filho A, Kanamura CT, Medeiros-Netto G: Differential reactivity for galectin-3 in Hürtle cell adenomas and carcinomas. Endocrinol Pathol 2001, 12, 275-279.
15. Niedobitek C, Niedobitek F, Lindenberg G, Bachler B, Neudeck H, Zuschneid W, Hopfenmuller W: Expression of galectin-3 in thyroid gland and follicular cell tumors of the thyroid. A critical study of its possible role in preoperative differential diagnosis. Pathologe 2001, 22, 205-213.
16. Niedziela M, Maceluch J, Korman E: Galectin-3 is not an universal marker of malignancy in thyroid disease in children and adolescents. J Clin Endocrinol Metab 2002, 87, 4411-4415.
17. Orlandi F, Saggiorato E, Pivano G, Puligheddu B, Termine A, Cappia S, Giuli P, Angeli A: Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 1998, 58, 3015-3020.
18. Rye PD, Fodstad O, Emilsen E: Invasion potential and N-acetylgalactosamine expression in a human melanoma model. Int J Cancer 1998, 75, 609-614.
19. Sahoo S, Hoda SA, Rosai J, DeLellis RA: Cytokeratin 19 immunoreactivity in the diagnosis of papillary thyroid carcinoma, a note of caution. Am J Clin Pathol 2001, 116, 696-702.
20. Saggiorato E, Cappia S, Giuli P, Mussa A, Pancani G, Caraci P, Angeli A, Orlandi F: Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 2001, 86, 5152-5158.
21. Schoepner H, Raz A, Ho SB: Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. Cancer 1975, 75, 2818-2826.
22. Shimamura T, Sakamoto M, Ino Y, Shimada K, Kosuge T, Sato Y, Tanaka K, Sekihara H, Hirohashi S: Clinicopathological significance of galectin-3 expression in ductal adenocarcinoma of the pancreas. Clin Cancer Res 2002, 8, 2570-2575.
23. Takano T, Sumizaki H, Nakano K, Kuma K, Amino N: Increased expression of CD44 variants in differentiated thyroid cancers. Jpn J Cancer Res 1996, 87, 1245-1250.
24. Xu X-C, el-Naggar AK, Lotan R: Differential expression of galectin-3 and galectin-1 in thyroid tumors. Am J Pathol 1995, 147, 815-822.